Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Zahra Dantes, Chao Fang, Helmut Friess, Ingrid Herr, Jingxiong Hu, Kuirong Jiang, Christoph Kahlert, Jörg Kleeff, Bo Kong, Hongzhen Li, Martin Loos, Zipeng Lu, Christoph W Michalski, Shuang Nie, Yiqi Niu, Maximilian Reichert, Susanne Roth, Kathleen Schuck, Shanshan Shen, Zhao Shi, Yifeng Sun, Yoshiaki Sunami, Lei Wang, Yuanyuan Yu, Lingling Zhang, Zhiheng Zhang, Siqi Zhou, Xiaoping Zou

Ngôn ngữ: eng

Ký hiệu phân loại: 597.95 *Sauria (Lizards)

Thông tin xuất bản: United States : Cell reports. Medicine , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 679835

Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive and characterized by pronounced desmoplasia. PDAC cells communicate with cancer-associated fibroblasts (CAFs) in a paracrine/reciprocal manner, substantially promoting tumor growth and desmoplastic responses. This study highlights the critical role of anterior gradient 2 (AGR2), an endoplasmic reticulum protein disulfide isomerase, secreted by PDAC cells to activate CAFs via the Wnt signaling pathway. Activated CAFs, in turn, secrete insulin-like growth factor 1 (IGF1), which enhances AGR2 expression and secretion in PDAC cells through the IGF1 receptor (IGF1R)/c-JUN axis. Within PDAC cells, AGR2 acts as a thioredoxin, aiding the folding and cell surface presentation of IGF1R, essential for PDAC's response to CAF-derived IGF1. This reciprocal AGR2/IGF1 signaling loop intensifies desmoplasia, immunosuppression, and tumorigenesis, creating a harmful feedback loop. Targeting both pathways disrupts this interaction, reduces desmoplasia, and restores anti-tumor immunity in preclinical models, offering a promising therapeutic strategy against PDAC.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH